Who is sponsoring NCT04936633?

NCT04936633 is sponsored by Young Shin Song.

What drugs are being tested in NCT04936633?

Interventions in NCT04936633: Intervention by medical staff based on a cloud system.

What condition does NCT04936633 study?

NCT04936633 studies Type 1 Diabetes Mellitus.

Is NCT04936633 still recruiting?

NCT04936633 is currently completed. Last updated 25 October 2022.

Last reviewed 2022-10-25 · How we verify

NCT04936633

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of FSGM Cloud-based Remote Intervention for Insulin-dEpendent Diabetic Patients (FRIEND)

Completed NA Last updated 25 October 2022

What this trial tests

NA trial testing Intervention by medical staff based on a cloud system in Type 1 Diabetes Mellitus in 36 participants. Completed in 30 April 2022.

Timeline

30 June 2021

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	Young Shin Song
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	30 June 2021
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	1 location across South Korea

Drugs / interventions tested

Intervention by medical staff based on a cloud system

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →

Sponsor

Young Shin Song

Who can join

Adults 19 to 75, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy of remote intervention by medical staff based on a cloud system of continuous glucose monitoring data in patients with insulin-dependent diabetes using flash sensor-based glucose monitoring (FSGM).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

FGM-based remote intervention for adults with type 1 diabetes: The FRIEND randomized clinical trial.
Lee J, Lee MH, Park J, Kim KS, et al · · 2022 · cited 6× · PMID 36506077 · DOI 10.3389/fendo.2022.1054697

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04936633 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Young Shin Song
Last refreshed: 25 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04936633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing